ENB Therapeutics
Latest round
- Series A
Last raised
- Sep 2018
Total raised
- $2.3M
Investors
- 4
About ENB Therapeutics
ENB Therapeutics, Inc.Founded in 2015 and headquartered in New York, US, ENB Therapeutics specializes in cancer therapies. Its latest deal occurred on September 20, 2018.ENB Therapeutics focuses on developing innovative therapies that target the tumor microenvironment, particularly for treating drug-resistant cancers. Their core products involve small molecules designed to inhibit the endothelin B receptor (ETBR), which plays a critical role in maintaining the 'cold' tumor phenotype by preventing immune cell infiltration. By turning off this receptor, ENB Therapeutics aims to create 'hot' tumors that allow immune cells to effectively attack cancer cells. The company’s lead compound, ENB-003, is currently in collaboration with Coherus Biosciences in clinical trials for ovarian cancer.ENB Therapeutics generates revenue primarily through strategic partnerships and clinical collaborations with other biotechnology firms and research institutions. The company engages in B2B transactions, particularly through agreements that facilitate the development of their therapeutic products, such as ENB-003. These collaborations may involve milestone payments and royalties based on the successful advancement of drug candidates through clinical trials. The revenue structure is designed to capitalize on partnerships that enhance their product development pipeline and expand their market reach in oncology. The company is focused on the development of ENB-003 and aims to enhance its portfolio with new products targeting other oncology indications. Geographic expansion is also on the agenda, with a specific focus on increasing their market presence in Europe and North America.
Who invested in ENB Therapeutics
4 investors across 1 round
See all investors in ENB Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Sep 20, 2018
Amount
$2.3M
Investors
Questions about ENB Therapeutics
Who invested in ENB Therapeutics?
ENB Therapeutics has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ENB Therapeutics raised?
ENB Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did ENB Therapeutics last raise money?
ENB Therapeutics's most recent round on record is a Series A, in Sep 2018.
What does ENB Therapeutics do?
ENB Therapeutics is a biotechnology company.
Where is ENB Therapeutics headquartered?
ENB Therapeutics is headquartered in New York, US.
Which VCs invest in companies like ENB Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at ENB Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like ENB Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.